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Aim: To investigate the prognostic role of neutrophil percentage-to-albumin ratio (NPAR) in muscle-
invasive bladder cancer (MIBC) patients treated with neoadjuvant chemotherapy (NAC) and radical cys-
tectomy (RC). Patients & methods: 213 patients were included. Inclusion criteria: Nonmetastatic, MIBC
(cT2-T4aN0M0), at least three cycles of NAC, undergone RC and with blood count within 30 days before
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NAC. Results: Five-years overall survival (OS) with NPAR >18 was 34.06% (95% CI: 18.3–50.5) and 65.37%
(95% CI: 52.4–75.6) with NPAR <18. Five years cancer-specific survival (CSS) with NPAR >18 was 42.9%
(95% CI: 23.9–60.7) and 74.5% (95% CI: 62.6–83.1) with NPAR <18 (p < 0.001). In multivariable analysis,
NPAR increased OS of 1.3 points and CSS of 4.37 points. Conclusion: High NPAR prior to NAC seems to be
a strong predictor of OS and CSS in MIBC patients treated with NAC and RC.
Lay abstract: This research demonstrated that presence of a high neutrophil percentage-to-albumin ra-
tio in patients with muscle-invasive bladder cancer prior neoadjuvant chemotherapy and radical cystec-
tomy is associated with worse outcomes and reduced overall and cancer-specific survival. Thus, neutrophil
percentage-to-albumin ratio could be a useful biological marker in clinical practice to help predict out-
comes for patients with muscle-invasive bladder cancer.
First draft submitted: 15 January 2021; Accepted for publication: 22 March 2021; Published online:
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Bladder cancer (BC) represents the 10th most common cancer worldwide, with a higher incidence in developed
countries, and approximately 80% of tumors being diagnosed in elderly patients (age 65 years or older). Males are
three- to four-times more likely to develop the disease than women, but at the time of diagnosis females are more
likely to have locally advanced cancer [1,2]. Most BCs are related to exposure to environmental and occupational
chemicals, tobacco consumption being the most common risk factor [3,4]. Also, a number of industries such as
paint, dye, metal and petroleum processing can be incriminated in developing bladder neoplasia [5].
The most common type of BC is urothelial carcinoma, which occurs in 90% of all cases [6]. The majority of BCs
can be diagnosed at an early stage. Although 75% are nonmuscle-invasive tumors at first diagnosis, approximately
78% of patients relapse within 5 years [7,8].
The therapeutic algorithm of urothelial carcinoma depends on the depth of invasion of the neoplasia. The
treatment strategy of patients with nonmuscle-invasive cancer is transurethral resection of bladder tumor, often
followed by intravesical therapy of bacillus Calmette–Guérin or chemotherapy. The recommended therapy of
muscle-invasive BC (MIBC) comprises radical cystectomy (RC) with bilateral pelvic lymphadenectomy combined
with chemotherapy [9,10], after cisplatin-based neoadjuvant chemotherapy (NAC), which is associated with an 8%
absolute increase in 5-year survival [11]. NAC with platinum-based combination therapy prior to RC with pelvic
lymph node dissection (PLND) eradicates micrometastases, improving by a well-established 5% the overall 5-year
survival benefit compared with surgery alone [12–15].
Currently available predictive models in patients with BC after RC remain inaccurate and mainly depend on
clinicopathological factors. Survival rate at 5 years depends on stage, locoregional extension and distant metasta-
sis [16]. The most important prognostic factor is TMN (T: tumor extension; M: presence of distant metastasis;
N: lymphnodal involvement) stage, but also several other blood-based markers could be used as outcome predic-
tors such as neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio,
albumin-to-globulin ratio, C-reactive protein-to-albumin ratio, inflammation-based index and modified Glasgow
prognostic score [17,18].
NLR is reproducible, inexpensive and easily available. High neutrophil count reflects systemic inflammation,
which is linked to protumorigenic effect, while low lymphocyte count indicates poor antitumor immune response
of the host. Several studies have shown that elevated NLR leads to poor outcomes for patients with MIBC treated
with NAC and RC [19,20].
Recently, neutrophil percentage-to-albumin ratio (NPAR) has been studied as prognostic marker of mortality in
cardiogenic shock and its value was more sensitive than neutrophil count and albumin level alone. In pancreatic
ductal adenocarcinoma, several studies show a prolonged median survival in patients with lower levels of NAR,
which also proved predictive of complete remission to neoadjuvant chemoradiation in rectal cancer [21–23].
The aim of our multicenter study was to investigate the prognostic role of NPAR in patients with MIBC treated
with NAC and RC.
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Patients & methods
Patients selection & data collection
Institutional review board approval at each institution was obtained, with all participating sites providing institu-
tional data sharing agreements prior to the initiation of the study. Inclusion criteria were nonmetastatic, muscle
invasive (cT2-T4aN0M0) urothelial carcinoma, received at least three cycles of cisplatin-based NAC, undergone
RC with PLND and had blood count data available within 30 days before starting first NAC cycle to calculate
NPAR. Patients were excluded if they had <3 cycles of cisplatin-based NAC (14 patients), no PLND performed
(three patients) or had variant histology (15 patients). A total of 213 out of 245 patients treated between 1 January
2008 and 31 December 2013 at nine academic institutions met the inclusion criteria. Demographical, clinical,
pathological and outcomes data were collected and entered in a computerized database. Data integrity, completeness
and quality were ensured through internal and external revisions.
Data extraction
The neutrophil percentage corresponds to the percentage of neutrophils in white blood cells. The NPAR was
calculated as the neutrophil percentage divided by albumin concentration in the same blood samples using the
formula: (neutrophil percentage [%] × 100/albumin [g/dl]).
Management & follow-up
All patients had at least three cycles of cisplatin-based NAC followed by RC and PLND with curative intent.
Informed consent was obtained from each patient. Pathological evaluation was carried out according to the tumor
node metastasis system of the Union for International Cancer Control and to the 1973 WHO grading classification.
All patients were generally followed according to European Association of Urology (EAU) guidelines at that time
and institutional protocols. Patients had regular follow-up examinations in the outpatient clinic 3, 6, 12 and
24 months after surgery, and annually thereafter. The clinical follow-up included computed tomography at 6, 12
and 24 months and if clinically indicated. Local recurrences were defined as soft tissue mass ≥2 cm occurring within
the field of PLND and cystectomy below the aortic bifurcation. Distant recurrences/metastases were defined as
those occurring outside the pelvis. End points were time to death (overall survival [OS]) and death due to BC
(cancer-specific survival [CSS]). Cause of death was determined by the treating physician, based on chart review
corroborated by death certificates when possible.
Statistical analysis
Using a receiver operating characteristic curve, we determined that a NPAR cut-off of 18 provided the optimal
balance between sensitivity and specificity in our cohort, so patients were classified into a low and high NPAR
group (NPAR ≤18 or NPAR >18). Association of NPAR with categorical variables was assessed using χ2 tests;
differences in continuous variables were analyzed using Mann–Whitney U-test. Kaplan–Meier method was used
to estimate disease-free survival, OS and CSS; log-rank tests were applied for pair wise comparison of survival.
Univariable and multivariable Cox regression models addressed associations with OS and CSS adjusting for the
effects of standard clinical and pathological features. Harrell’s concordance index (C index) was used to measure
the ordinal predictive power of the model for disease-free survival (data not shown), OS and CSS. All p-values were
two sided, and statistical significance was defined as p < 0.05. Statistical analyses were performed using Stata 11.0
statistical software (Stata Corp., TX, USA).
Results
Baseline clinical & pathological features
Median NPAR was 15.45 (interquartile range [IQR]: 12.49–18.88) and ranged from 1.51 to 30.05. A total
of 152 (71.4%) patients treated with RC after NAC for MIBC had NPAR <18. There was no difference
between this group and patients with NPAR ≥18 in terms of gender, American society of Anesthesiologists
(ASA) score, Eastern cooperative oncology group (ECOG) score, preoperative hydronephrosis, hemoglobin, NAC
regimen (three vs >3 cycles), histology (pure, nonpure urothelial cancer [UC]), nodes and metastasis status at RC,
lymphadenectomy extension, positive nodes and node status after RC, pathological stage, and adjuvant treatment
(chemo/radiotherapy). However, there were differences among age (p = 0.004), pre-NAC creatinine (p = 0.001),
cholesterol (p = 0.02) and fibrinogen (p = 0.01), BMI (p = 0.001), NLR (p < 0.001), clinical stage (p = 0.03),
and nodes removed (p = 0.0007) (Table 1).
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Table 1. Association of clinical and pathological features with neutrophil percentage-to-albumin ratio in 213 patients
treated with radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.
All cohort NPAR <18 NPAR ≥18 p-value
Total, n (%) 213 152 (71.4) 61 (28.6)
Mean age, years (SD) 65.86 (10) 64.55 (8.9) 69.13 (12) 0.004
Gender, n (%)
Males 176 (82.6) 126 (82.9) 50 (82) 0.87
Females 37 (17.4) 26 (17.1) 11 (18)
ASA score, n (%)
1 6 (2.8) 4 (2.6) 2 (3.3) 0.69
2 99 (46.5) 67 (44.1) 32 (52.4)
3 101 (47.4) 76 (50) 25 (41)
4 7 (3.3) 5 (3.3) 2 (3.3)
ECOG score, n (%)
0 121 (56.8) 88 (57.9) 33 (54.1) 0.14
1 69 (32.3) 52 (34.2) 17 (27.9)
2 13 (6.1) 8 (5.2) 5 (8.2)
3 4 (2) 1 (0.7) 3 (4.9)
4 6 (2.8) 3 (2) 3 (4.9)
Preoperative hydronephrosis, n (%)
No 165 (77.5) 121 (79.6) 44 (72.1) 0.23
Yes 48 (22.5) 31 (20.4) 17 (27.9)
Hemoglobin mean (SD) 12.61 (1.96) 12.54 (2) 12.78 (1.8) 0.19
Creatinine mean (SD) 1.17 (0.64) 1.24 (0.72) 1.01 (0.29) 0.001
BMI mean (SD) 25.92 (3.68) 26.57 (3.67) 24.29 (3.18) 0.001
Cholesterol mean (SD) 202 (38.17) 198.2 (36.96) 211.5 (39.79) 0.02
Fibrinogen mean (SD) 3.1 (1.2) 2.93 (1.19) 3.53 (1.17) 0.01
NLR mean (SD) 2.77 (1.68) 2.1 (1.03) 4.43 (1.83) <0.001
NAC cycles, n (%)
=3 148 (69.5) 112 (73.7) 36 (59) 0.051
3 65 (30.5) 40 (26.3) 25 (41)
Clinical stage at RC, n (%)
CIS 4 (1.9) 4 (2.6) 0 (0) 0.03
T1 27 (12.7) 21 (13.8) 6 (9.8)
T2 99 (46.4) 63 (41.5) 36 (59)
T3 56 (26.3) 47 (30.9) 7 (14.8)
T4 27 (12.7) 17 (11.2) 10 (16.4)
Histology, n (%)
Pure UC 184 (86.4) 129 (84.9) 55 (90.2) 0.3
Nonpure UC 29 (13.6) 23 (15.1) 6 (9.8)
Node status at RC, n (%)
N0 193 (90.6) 142 (93.4) 51 (83.6) 0.07
N1 13 (6.3) 6 (4) 7 (11.5)
N2 7 (3.3) 4 (2.6) 3 (4.9)
Metastasis status at RC, n (%) 0.79
No 207 (97.2) 148 (97.4) 59 (96.7)
Yes 6 (2.8) 4 (2.6) 2 (3.3)
Lymphadenectomy extension
Standard 171 (80.3) 122 (80.3) 49 (80.3) 0.99
Extended 42 (19.7) 30 (19.7) 12 (19.7)
Boldface values represent statistically significant p  0.05.
ASA: American society of Anesthesiologists; CIS: Carcinoma in situ; ECOG: Eastern cooperative oncology group; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio;
NPAR: Neutrophil percentage-to-albumin ratio; RC: Radical cystectomy; SD: Standard deviation; UC: Urothelial cancer.
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Table 1. Association of clinical and pathological features with neutrophil percentage-to-albumin ratio in 213 patients
treated with radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (cont.).
All cohort NPAR <18 NPAR ≥18 p-value
Nodes removed 18.21 (9.35) 19.6 (9.1) 14.77 (9.14) 0.0007
Positive nodes 1.2 (3.34) 1.32 (3.86) 0.91 (1.34) 0.25
Pathological stage, n (%)
T0 47 (22.1) 38 (25) 9 (14.8) 0.33
Tis 13 (6.1) 9 (5.9) 4 (6.5)
Ta 9 (4.2) 4 (2.6) 5 (8.2)
T1 18 (8.5) 13 (8.5) 5 (8.2)
T2 42 (19.7) 32 (21.1) 10 (16.4)
T3 58 (27.2) 38 (25) 20 (32.8)
T4 26 (12.2) 18 (11.9) 8 (13.1)
Node status after RC, n (%)
N0 183 (85.9) 132 (86.8) 51 (83.6) 0.11
N1 9 (4.2) 8 (5.3) 1 (1.7)
N2 17 (7.9) 11 (7.3) 6 (9.8)
N3 4 (2) 1 (0.6) 3 (4.9)
Adjuvant treatment, n (%)
No 191 (89.7) 135 (88.8) 56 (91.8) 0.64
Chemotherapy 12 (5.6) 10 (6.6) 2 (3.3)
Radiotherapy 10 (4.7) 7 (4.6) 3 (4.9)
Boldface values represent statistically significant p  0.05.
ASA: American society of Anesthesiologists; CIS: Carcinoma in situ; ECOG: Eastern cooperative oncology group; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio;
NPAR: Neutrophil percentage-to-albumin ratio; RC: Radical cystectomy; SD: Standard deviation; UC: Urothelial cancer.
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Figure 1. Comparison of overall survival in 213 patients with bladder cancert treated with neoadjuvant
chemotherapy followed by radical cystectomy. (A) Neutrophil-to-lymphocyte ratio. (B) Neutrophil
percentage-to-albumin ratio.
Association of NPAR with OS
During follow-up 65 (30.5%) out of 213 patients died, median follow-up duration was 72 months (IQR: 52–98).
Five-years OS estimates among patients with NPAR >18 were 54.2% (95% CI: 38.9–67.2) and 83% (95% CI:
75.9–88.2) in those with NPAR <18, respectively (p < 0.001); and in patients with NLR ≥3 was 62.6% (95%
CI: 48.2–74) compared with 80.9% (95% CI: 73.4–86.5) in patients with NLR <3 (p = 0.001) (Figure 1). In
univariable analysis, both categorical and continuous NLR (hazard ratio [HR]: 2.17; 95% CI: 1.32–3.54; p = 0.002)
and NPAR (HR: 2.9; 95% CI: 1.76–4.78; p < 0.001) were significantly associated with worse OS. In multivariable
analysis, independent predictors of OS were patient gender (HR: 1.92; 95% CI: 1.07–3.43; p < 0.02), BMI (HR:
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Table 2. Preoperative multivariable Cox regression analyses predicting overall survival.
Variables Model 1 Model 2 Model 3
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age cont. 0.98 0.96–1.01 0.29 0.98 0.96–1.01 0.26 0.98 0.95–1.00 0.11
Gender (males vs females) 1.92 1.07–3.43 0.02 1.88 1.05–3.36 0.03 1.92 1.07–3.44 0.02
BMI cont. 0.88 0.81–0.95 0.002 0.89 0.82–0.96 0.005 0.9 0.83–0.98 0.01
Hydronephrosis (no vs yes) 1.91 1.1–3.29 0.02 1.62 0.92–2.84 0.09 1.7 0.97–2.96 0.06
Hystology (pure vs nonpure
UC)
0.95 0.43–2.06 0.89 0.92 0.42–1.99 0.83 1.08 0.5–2.36 0.83
NAC (3 cycles vs 3 cycles) 1.32 0.78–2.23 0.29 1.3 0.77–2.19 0.31 1.32 0.78–2.22 0.29
Stage, Tis/T1
T2 1.78 0.7–4.52 0.22 1.44 0.55–3.72 0.45 1.53 0.6–3.9 0.36
T3 1.98 0.73–5.37 0.17 1.85 0.68–5 0.22 1.98 0.74–5.32 0.17
T4 5.44 2.02–14.66 0.001 4.9 1.8–13.32 0.002 4.83 1.79–13.06 0.002
Nodes + (no vs yes) 1.43 0.65–3.1 0.36 1.46 0.67–3.17 0.32 1.26 0.58–2.73 0.54
Metastasis + (no vs yes) 1.12 0.14–8.56 0.9 1.02 0.13–7.83 0.98 1.16 0.15–8.77 0.88
NLR (3 vs 3) - - - 1.81 1.06–3.09 0.02 - - -
NPAR (18 vs 18) - - - - - - 2.28 1.31–3.99 0.004
Harrell’s C index 71.5 72.1 72.8
Boldface values represent statistical significance.
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Figure 2. Comparison of cancer-specific survival according to (A) neutrophil-to-lymphocyte ratio and to (B)
neutrophil percentage-to-albumin ratio in 213 patients with bladder cancer treated with neoadjuvant chemotherapy
followed by radical cystectomy.
0.88; 95% CI: 0.81–0.95; p < 0.002), hydronephrosis (HR: 1.91; 95% CI: 1.1–3.29; p < 0.02) and tumor stage
T4 (HR: 5.44; 95% CI: 2.02–14.66; p < 0.001). Both NLR (model 2, Table 2) and NPAR (model 3, Table 2)
retain a statistical significant association with worse OS in multivariable analysis. However, when NLR was added
to the predictive model the Harrell’s C index increased only with 0.6 up to 72.1 points, but when we added NPAR
instead of NLR the discrimination of the model increased with 1.3 up to 72.8 points (Table 2).
Association of NPAR with CSS
During follow-up 48 (22.5%) out of 213 patients died due to BC, median follow-up duration was 72 months (IQR
52–98). Five-years CSS estimates among patients with NPAR >18 were 63.5% (95% CI: 47.8–75.5) and 87.4%
(95% CI: 80.7–91.9) in those with NPAR <18, respectively (p < 0.001); and in patients with NLR≥3 was 64.2%
(95% CI: 49.8–75.4) compared with 88.3% (95% CI: 81.6–92.7) in patients with NLR <3 (p = 0.001) (Figure 2).
In univariable analysis, both categorical and continuous NLR (HR: 2.9; 95% CI: 1.64–5.13; p < 0.001) and
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Table 3. Preoperative multivariable Cox regression analyses predicting cancer-specific survival.
Variables Model 1 Model 2 Model 3
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age cont. 0.98 0.95–1.01 0.41 0.98 0.95–1.01 0.37 0.98 0.95–1.00 0.18
Gender (males vs females) 1.48 0.72–3.03 0.27 1.44 0.7–2.95 0.31 1.45 0.7–2.98 0.31
BMI cont. 0.91 0.83–0.99 0.04 0.92 0.84–1.01 0.09 0.94 0.86–1.03 0.2
Hydronephrosis (no vs yes) 2.02 1.08–3.76 0.02 1.6 0.85–3.02 0.14 1.75 0.93–3.31 0.08
Hystology (pure vs nonpure
UC)
0.76 0.29–1.99 0.58 0.72 0.27–1.89 0.5 0.88 0.33–2.31 0.8
NAC (3 cycles vs 3 cycles) 1.13 0.6–2.12 0.68 1.12 0.6–2.09 0.7 1.13 0.6–2.11 0.69
Stage, Tis/T1 Ref. Ref. Ref.
T2 1.35 0.48–3.82 0.56 1 0.34–2.88 0.99 1.18 0.41–3.36 0.74
T3 1.77 0.6–5.24 0.29 1.58 0.54–4.7 0.39 1.84 0.62–5.42 0.26
T4 4.62 1.56–13.65 0.006 3.84 1.27–11.59 0.01 3.89 1.3–11.67 0.01
Nodes + (no vs yes) 0.99 0.34–2.87 0.99 1.03 0.35–2.97 0.95 0.85 0.29–2.45 0.76
Metastasis + (no vs yes) 1.44 0.18–11.21 0.72 1.29 0.16–10.12 0.8 1.44 0.18–11.19 0.72
NLR (3 vs 3) - - - 2.62 1.43–4.79 0.002 - - -
NPAR (18 vs 18) - - - - - - 2.82 1.48–5.36 0.002
Harrell’s C index 67.2 70.2 71.57
Boldface values represent statistical significance.
C index: Concordance index; HR: Hazard ratio; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio; NPAR: Neutrophil percentage-to-albumin ratio; Ref.: Reference;
UC: Urothelial cancer.
NPAR (HR: 3.23; 95% CI: 1.81–5.75; p < 0.001) were significantly associated with worse CSS. In multivariable
analysis, independent predictors of CSS were BMI (HR: 0.91; 95% CI: 0.83–0.99; p = 0.04), hydronephrosis
(HR: 2.2; 95% CI: 1.08–3.76; p = 0.02) and tumor stage T4 (HR: 4.62; 95% CI: 1.56–13.65; p = 0.006). Both
NLR (model 2, Table 3) and NPAR (model 3, Table 3) retain a statistical significant association with worse CSS
in multivariable analysis, together with T4 pathological tumor stage. Even more, when NLR was added to the
predictive model the Harrell’s C index increased with 3 points up to 70.2, but when we added NPAR instead of
NLR the discrimination of the model increased with 4.37 up to 71.57 points (Table 3).
Discussion
We showed that elevated level of NPAR was associated with worse oncological outcomes in patients with MIBC
treated with NAC followed by RC with PLND. Furthermore, when we added NPAR in a preoperative predictive
model in both OS and CSS increased the discrimination compared with addition of NLR.
According to our findings, it seems that as was shown in the case of patients with pancreatic cancer and
rectal cancer [22,24], NPAR could be a useful biomarker for predicting outcomes in patients with MIBC. Even in
nonneoplastic conditions elevated NPAR was related with increased risk of all-cause mortality [25], and elevated
admission NPAR was linked to higher rate of death during hospitalization in patients with ST-elevation myocardial
infarction [26]. Other studies demonstrated that high NPAR in patients with coronary artery disease and patients
with acute kidney injury was correlated with 30-, 90- and 365-day all-cause-mortality [27,28]. Also, an increased
level of NPAR was associated with high mortality rate in patients with cardiogenic shock [21].
In a recent multicentric study NLR with a cut-off of three seems to be an important prognostic factor, correlated
to disease recurrence, progression and CSS in patients with primary T1 HG/G3 non-muscle invasive bladder
cancer (NMIBC) treated with intravesical bacillus Calmette–Guérin therapy [29].
The limitations of our multicentric study should also be recognized. The retrospective design of the study
introduces limitations such as the absence of data on potential confounding factors, differential losses to follow-up
and information bias [20]. It also may lead to an inaccurate recall, making it difficult to distinguish the exposed and
the nonexposed individuals, in order to take drastic conclusions. Second, histology specimens were not examined
by central pathology and major risk factors, lymphovascular invasion and variant histology not being evaluated.
Also, the patients’ comorbidities could have influenced the decision related to undergoing instillation therapy or
surgery, resulting in exclusion from our study. In the end, we have to mention that our NPAR cutoff of 18 was not
studied before regarding the prognostic character in patients with invasive bladder neoplasia, as our intent was to
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study the validity of biomarker at this cut-off value. In fact, negative results of NPAR prognostic factor might not
be published, causing potential publication bias.
Conclusion
By using a cutoff of 18, NPAR appears to be a clinically significant predictor of worse oncologic outcomes in
patients with MIBC treated with NAC and RC. Even more, it increases the discrimination in predicting both OS
and CSS in comparison with NLR ratio.
Future perspective
The role of NPAR as prognostic factor in MIBC is quickly growing. Although further studies are required in order
to evaluate the weight of this parameter and maximize its utility, the possibility to use an inexpensive and easily
available hematologic test to predict OS and CSS of patients with MIBC could be particularly relevant in the future
clinical practice.
Summary points
• Bladder cancer (BC) represents the 10th most common cancer worldwide, with 78% of patients relapsing within
5 years from conservative treatment (transurethral resection of bladder tumor).
• The recommended therapy for muscle-invasive BC (MIBC) comprises radical cystectomy (RC) with bilateral pelvic
lymphadenectomy combined with chemotherapy.
• Currently available predictive models in patients with BC after RC remain poor and inaccurate.
• Neutrophil percentage-to-albumin ratio (NPAR) corresponds to the percentage of neutrophils in white blood cells
and is calculated as the neutrophil percentage divided by albumin concentration in the same blood sample using
the formula: (neutrophil percentage [%] × 100/albumin [g/dl]).
• Of the 213 patients included, 5-years overall survival estimates among patients with NPAR >18 were 54.2% (95%
CI: 38.9–67.2) and 83% (95% CI: 75.9–88.2) in those with NPAR <18 (p < 0.001).
• Similarly, 5-years cancer-specific survival estimates among patients with NPAR >18 were 63.5% (95% CI:
47.8–75.5) and 87.4% (95% CI: 80.7–91.9) in those with NPAR <18 (p < 0.001).
• Elevated level of NPAR was associated with worse oncological outcomes in patients with MIBC treated with
neoadjuvant chemotherapy followed by RC with pelvic lymph node dissection.
• NPAR appears to be a clinical significant predictor of worse oncologic outcomes in patients with MIBC treated
with neoadjuvant chemotherapy and RC both on overall and cancer-specific survival.
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